On April 27, 2022 NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, reported it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, to be held in Chicago, June 3-7, 2022 (Press release, NeoImmuneTech, APR 27, 2022, View Source [SID1234613069]). These include one poster discussion and two poster displays.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: "We are pleased that the ASCO (Free ASCO Whitepaper) Scientific Program Committee selected our abstract on the efficacy and safety of NT-I7 in combination with pembrolizumab for a poster discussion. While the abstract was based on data cutoff as of January 14, 2022, the actual Phase 2a data presented and discussed at the congress will have a few additional months of follow-up. They will shed new light on the benefit of combining NT-I7 with a checkpoint inhibitor (CPI) in patients with immune-cold microsatellite stable colorectal cancer or pancreatic cancer and in those who progressed on previous CPI treatment. We are also excited to report progress made with NT-I7 administration after CAR-T infusion, another important area of potential NT-I7 use."

NIT presentations at 2022 ASCO (Free ASCO Whitepaper) Annual Meeting:

Primary
Author

Abstract Title

Presentation details

Naing, A

Efficacy and Safety of NT-I7, Long-Acting
Interleukin-7, plus Pembrolizumab in
patients with advanced solid tumors: results
from the Phase 2a study

Abstract #2514
Poster discussion Session: Developmental Therapeutics
-Immunotherapy
June 5, 2022
11:30 AM-1:00 PM;
8:00 AM-11:00 AM CDT
Gastman, B

A phase 1b/2a study of safety and efficacy of
NT-I7 in combination with anti-PD-L1
(atezolizumab) in patients with anti-PD-
1/PD-L1 naïve or relapsed/refractory (R/R)
high-risk skin cancers: The phase 1b report.

Abstract #9561
Poster display Session:
Melanoma/Skin Cancers
June 6, 2022
1:15 PM-4:15 PM CDT
Ghobadi, A

Trial in Progress: A phase 1b study evaluating
the safety, tolerability and preliminary anti-
tumor activity of NT-I7 (efineptakin alfa), a
long-acting human IL-7, post-tisagenlecleucel
in subjects with relapsed/refractory large B-
cell lymphoma

Abstract # TPS7596
Poster display – Trial in
progress (TiP) Poster Session:
Hematologic Malignancies
– Lymphoma and Chronic Lymphocytic Leukemia
June 4, 2022
8:00 AM- 11:00 AM CDT
About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.